Breo Ellipta (fluticasone furoate/vilanterol trifenatate) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) and asthma. Breo Ellipta’s cost may depend on factors such ...
The prescribed dosage for Breo Ellipta may depend on your individual treatment plan. Factors like your condition, medical history, age, and other treatments you take may affect your dosage of Breo ...
Breo Ellipta (fluticasone furoate/vilanterol trifenatate) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat the following conditions in adults: ...
Breo Ellipta (fluticasone furoate/vilanterol) is a brand-name medication prescribed for chronic obstructive pulmonary disease (COPD) and asthma in adults and some children. As with other drugs, Breo ...
Credit: Getty Images. The FDA has expanded the approval of Breo Ellipta to include maintenance treatment of asthma in children 5 to 17 years of age. The Food and Drug Administration (FDA) has expanded ...
RESEARCH TRIANGLE PARK, NC and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 30, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, ...
LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ...
GlaxoSmithKline and Theravance’s Breo has been recommended for approval by an FDA advisory committee for asthma, but only in adults. Breo is already approved to treat chronic obstructive pulmonary ...
The US Food and Drug Administration (FDA) has approved the combination of fluticasone furoate/vilanterol (Breo Ellipta, GlaxoSmithKline/Theravance) for the once-daily ...
The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results